August 03, 2012

U.S. FDA Approves ZALTRAP® (ziv-aflibercept) after Priority Review for Previously Treated Metastatic Colorectal Cancer

 

U.S. FDA Approves ZALTRAP® (ziv-aflibercept) after Priority Review for Previously Treated Metastatic Colorectal Cancer

Paris, France and Tarrytown, NY – August 3, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) approved ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, in combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI), for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen.